Pharvaris N.V.
Pharvaris N.V. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency on June 15, 2027. There are 3 upcoming events on record.
Cash runway is approximately 25.6 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| June 15, 2027 | Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | Trial Milestone | Phase 3 |
| June 15, 2027 | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Trial Milestone | Phase 2/Phase 3 |
| December 15, 2028 | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Trial Milestone | Phase 3 |
Track PHVS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PHVS in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.